Risk of hyperglycemia attributable to everolimus in cancer patients: A meta-analysis.

about

Risk of hyperglycemia attributable to everolimus in cancer patients: A meta-analysis.

Item

http://www.wikidata.org/entity/Q52871581

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

Risk of hyperglycemia attributable to everolimus in cancer patients: A meta-analysis.

@en

Risk of hyperglycemia attributable to everolimus in cancer patients: A meta-analysis.

@nl

type

Item

label

Risk of hyperglycemia attributable to everolimus in cancer patients: A meta-analysis.

@en

Risk of hyperglycemia attributable to everolimus in cancer patients: A meta-analysis.

@nl

prefLabel

Risk of hyperglycemia attributable to everolimus in cancer patients: A meta-analysis.

@en

Risk of hyperglycemia attributable to everolimus in cancer patients: A meta-analysis.

@nl

P1476

Risk of hyperglycemia attributable to everolimus in cancer patients: A meta-analysis.

@en

P2093

Kevin Y Xu

http://www.w3.org/2001/XMLSchema#string

Raji Shameem

http://www.w3.org/2001/XMLSchema#string

Shenhong Wu

http://www.w3.org/2001/XMLSchema#string

P2860

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44).

Hyperglycemia, a neglected factor during cancer progression

The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma.

Everolimus for advanced pancreatic neuroendocrine tumors.

Diabetogenic glucose and insulin concentrations modulate transcriptome and protein levels involved in tumour cell migration, adhesion and proliferation.

P304

1196-1203

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

meta-analysis

P356

10.3109/0284186X.2016.1168939

http://www.w3.org/2001/XMLSchema#string

P433

9-10

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-05-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27142123

http://www.w3.org/2001/XMLSchema#string

P921

hyperglycemia